Based on a consideration of the results of these clinical studies, the FDA approved atezolizumab or durvalumab (the PD-L1 inhibitors) combined with chemotherapy for the first-line treatment of ES-SCLC. The gene discussed is CD274; the disease is small cell lung carcinoma.